Hair loss. Androgenic alopecia, unspecified
Conditions
Interventions
Intervention 1: Control group: Each session, patients are treated with injections of 20 million adipose-derived SVF cells in three sessions, one month apart. Intervention 2: Control group: Patients ar
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: men and women with inherited hormonal hair loss Age 18 years and older and less than 50 years Hamilton scores 2 to 5 in men and Ludwig scores 1 to 3 in women Complete patient consent to participate in the project
Exclusion criteria
Exclusion criteria: Platelet disorders Thrombocytopenia Patients receiving anticoagulants Patients with malignancy Receiving chemotherapy during the last 5 years Patients with sepsis Being a smoker Pregnancy Active wound or infection at the treatment site Do not receive any topical or systemic medication in the last 3 months Women with hyperprolactinemia Women with hormonal disorders or polycystic ovaries
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of hair loss. Timepoint: Before treatment and one month after the last session. Method of measurement: Trichoscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: One week after session. Method of measurement: Questionnaire and visit.;Satisfaction. Timepoint: One months after the last session. Method of measurement: Satisfaction Questionnaire and visit.;Tolerability. Timepoint: Each session after transplantation. Method of measurement: Questionnaire and visit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSona Zare
Skin and stem Cell Research Center, Tehran University of Medical Sciences
Outcome results
None listed